Highly Sensitive and Selective Method for Estimation of Formoterol at Sub-pg/mL in Human Plasma Using Shimadzu LCMS-8060NX

User Benefits

－Simple, selective and highly sensitive method with lower limit of quantification of 0.2 pg/mL.
－Linear dynamic range suitable for pharmacokinetic studies, spanning from 0.2 pg/mL to 100 pg/mL.
－Single-step sample extraction method that increases sample productivity.

Introduction

Formoterol is an inhaled long-acting beta2-adrenergic receptor agonist used as a bronchodilator in the management of asthma and COPD. It acts on bronchial smooth muscle to dilate and relax airways and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as salbutamol, combined with a long duration of action (12 hours) . Following single/multiple dose administration of formoterol, the drug exhibits very low bioavailability and requires a highly sensitive and selective quantification of formoterol from plasma. In this work, a highly sensitive, and selective method was developed for the accurate quantification of formoterol from plasma.
We therefore developed a new LCMS method to solve problems like low bioavailability and low extraction recovery. The developed method has a high level of accuracy and can detect very low concentration of formoterol in human plasma. We focused on making the extraction process easier, improving the chromatography, and increasing sensitivity. This helped us to develop the most sensitive bioanalytical LCMS method for formoterol in human plasma.

August 6, 2024 GMT